Abstract: The present invention is directed to the compounds of Formula (I)—inhibitors of the interaction of menin and MLL. The inhibitors described herein can be useful in the treatment of diseases or disorders associated with menin-MLL interaction, such as cancer. In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting/blocking menin-MLL interaction, methods of treating diseases or disorders associated with menin-MLL interaction, and methods of synthesizing these compounds.

Abstract: The present application is directed to compounds, pharmaceuticals, formulations, and methods for treating and preventing RNA virus infections, particularly infections in mammals. The present application also relates to treating and preventing diseases caused by RNA viruses. In preferred embodiments, the pharmaceuticals, formulations, and methods for treatment and prevention use liposomal aprotinin (Lip-APR).

Abstract: The present invention is generally directed to inhibitors of hematopoietic progenitor kinase 1 (HPK1) and FMS-like tyrosine kinase 3 (FLT3) gene, useful in the treatment of diseases and disorders modulated by said HPK1, and FLT3 having the Formula I:

Abstract: The invention relates to a new aqueous aprotinin-containing antiviral pharmaceutical composition with aprotinin activity from 50 KIU/ml to 950 KIU/ml, optionally containing excipients, for the prevention and treatment of acute respiratory viral infections (ARVI) (acute respiratory infection—ARI). The invention also relates to a new drug for the treatment and prevention of ARVI, comprising said composition in a form suitable for inhalation, nasal or drip use. The medicament can be a nasal spray, or a throat and mouth spray, placed in a vial or vial with a metering valve for a spray or with a dropper dispenser. The medicament can also be aqueous aprotinin-containing antiviral pharmaceutical composition, in a form suitable for inhalation, placed in a vial or vial, container or ampoule for inhalation by a nebulizer. The invention also relates to the use of VASPFC or a drug based on it for the prevention and treatment of ARVI.

Abstract: Substituted 3,4,12,12a-tetrahydro-1H-[1,4]-oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione of general formula 1, its stereoisomer, their prodrug, pharmaceutically acceptable salt, solvate, hydrate, and a crystalline or polycrystalline form thereof where: R1 is 7,8-difluoro-4,9-dihydrothieno[2,23-c][2]benzothiepin-4-yl, R2 is hydrogen or a protective group selected from a series comprising benzyl, (C1-C3 alkyl)oxycarbonyloxy, {[(C1-C3alkyl)oxycarbonyl]-oxy}methoxy, {[2-(C1-C3 alkyl)oxyethoxy]carbonyl}oxy, ({(1R)-2-[(C1-C3alkyl)oxy]-1-methylethoxy}carbonyl) oxy, {[(3S)-ethoxyfuran-3-yloxy]-carbonyl}oxy, [(ethoxy-2H-pyran-4-yloxy)carbonyl]oxy, {[(1-acetylazetidine)-3-yloxy]carbonyl}oxy, {[(C1-C3 alkyl)oxycarbonyl]oxy}methoxy, ({[2-(C1-C3 alkyl)oxyethoxy]carbonyl}oxy) methoxy.

Abstract: Substituted 3,4,12,12a-tetrahydro-1H-[1,4]-oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione of general formula 1, its stereoisomer, their prodrug, pharmaceutically acceptable salt, solvate, hydrate, and a crystalline or polycrystalline form thereof where: R1 is diphenylmethyl, bis(4-fluorophenyl)methyl, (3,4-difluorophenyl)(phenyl)methyl, (3,4-difluorophenyl)(2-methylsulfanylphenyl)methyl; R2 is hydrogen or a {[(C1-C3alkyl)oxycarbonyl]-oxy}methoxy and stereoisomers thereof.

Abstract: Influenza is an acute infectious respiratory disease caused by the influenza virus. It is part of the group of Acute Respiratory Viral Infections (ARVI). It occasionally spreads in the form of epidemics and pandemics. Currently, more than 2000 variants of the influenza virus differing in the antigen spectrum have been identified. Given that influenza is a serious threat to public health (worldwide, these annual epidemics lead to 3-5 million cases of severe illness, millions of hospitalizations, and up to 650,000 deaths), it seems appropriate to search for new anti-influenza drugs with improved characteristics.

Abstract: The present invention is generally directed to inhibitors of hematopoietic progenitor kinase 1 (HPK1), leucine rich repeat kinase 2 (LRRK2) protein, FMS-like tyrosine kinase 3 (FLT3) gene, interleukin-1 receptor-associated kinase 1 (IRAK1), interleukin-1 receptor-associated kinase 4 (IRAK4), and Janus kinases (JAKs), including Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2) useful in the treatment of diseases and disorders modulated by said HPK1, LRRK2, FLT3, IRAK1, IRAK4, and JAKs, having the Formula (I):

Abstract: The present invention is generally directed to inhibitors of protein tyrosine phosphatase enzymes useful in the treatment of diseases and disorders modulated by said enzymes and having the Formula (I):

Abstract: The present invention relates to a novel Noradrenergic and Specific Serotonergic Anxiolytic and Antidepressant (NaSSA) and a method for the production and use thereof for treating mental disorders. The subject of this invention is a novel noradrenergic and specific serotonergic drug for the treatment of mental disorders in humans, which is 2,8-dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride (A·HCl), a polymorphous modification thereof, and methods for the production and use thereof.

Abstract: The present invention is generally directed to inhibitors of BCL-2 proteins useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I):

Abstract: The present invention is generally directed to inhibitors of BCL-2 proteins useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I):

Abstract: This invention relates to a novel anti-coronavirus agent for COVID-19 (SARS-CoV-2) combination therapy. The agent comprises, in a therapeutically effective amount and ratio, aprotinin (APR) or a medicinal drug based thereon and a SARS-CoV-2 replication inhibitor. The aprotinin-based medicinal drug is preferably selected from the group consisting of Aprotex, Vero-Narcap, Ingitril, Contrykal, Kontrisel, Trasilol®, Ingiprol, Aprotimbin, Gordox®, Contriven, Trascolan, or Aerus. For SARS-CoV-2 replication inhibitor one can use favipiravir (FPV) or Remdesivir (RMD), or a medicinal drug based thereon. The favipiravir-based medicinal drug is preferably selected from the group consisting of Avigan, Favilavir, Avifavir, Coronavir, or Fabiflu. Further, the invention relates to a combination method to treat COVID-19 (SARS-CoV-2) by administering said anti-coronavirus agent to a patient with COVID-19.

Abstract: The present invention is generally directed to inhibitors of BCL-2 proteins useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (A):

Abstract: The present application relates to the new the pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including viral and bacterial pneumonia and COVID-19, using aprotinin (APR), ribavirin and / or nirmatrelvir (NIMR), the pharmaceutical kit and the pharmaceutical composition for this pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including COVID-19.

Abstract: The application relates to pharmaceutical combinations, methods, and therapies for the treatment and prevention of SARS-CoV-2 infection and related diseases. The combinations contain aprotinin and molnupiravir, and/or favipiravir. The application also includes related pharmaceutical kits. Further details are described in the specification.

Abstract: A pharmaceutical combination prevention and treatment of RNA virus infection and/or a disease associated with this infection, of acute respiratory viral infections (ARVI) and severe acute respiratory syndrome (SARS), including viral and bacterial pneumonia and COVID-19, using aprotinin (APR) and an anti-RNA ingredient. A pharmaceutical kit and pharmaceutical composition in the form of an aqueous solution (APC) or a lyophilizate (PCL) for a pharmaceutical combination treatment and prevention of RNA virus infection and/or a disease associated with this infection.

Abstract: The application relates to pharmaceutical combinations, methods, and therapies for the treatment and prevention of SARS-CoV-2 infection and related diseases. The combinations contain aprotinin, baricitinib, and/or remdesivir. The application also includes related pharmaceutical kits. Further details are described in the specification.

Abstract: The present invention is generally directed to inhibitors of BCL-2 proteins useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I):

Abstract: This invention relates to a novel anti-SARS-CoV-2 virus agent Antiprovir to be used for the prevention and treatment of coronavirus disease COVID-19. The use of a pharmaceutical composition, including Aprotex®, Gordox® and Aerus®, with aprotinin as the active ingredient and excipients, said pharmaceutical composition being anti-SARS-CoV-2 virus drug Antiprovir to be used for the prevention and treatment of coronavirus disease COVID-19. The drug Antiprovir for the prevention and treatment of coronavirus disease COVID-19, which is a pharmaceutical composition containing 0.1% wt. ÷ 0.2% wt. aprotinin, optionally 0.2 %wt. ÷ 1.0% wt. excipients, and the rest is water for injection.